[Hand-mirror cells acute lymphoblastic leukemia (L3)]. 1995

K Uemura, and H Otani, and K Sakamoto, and Y Sakanishi, and T Ota, and T Kobayashi, and N Ariyoshi, and A Shirahata
Central Clinical Laboratory, University of Occupational and Environmental Health, Kitakyusyu.

To our knowledge, this report represents the first confirmed case in Japan of a 15-year-old boy with acute lymphoblastic leukemia (ALL).L3 with hand-mirror cells (HMC) in the bone marrow. HMC lymphoid leukemia is an unusual variant of ALL in which the bone marrow lymphoblasts manifest distinctive hand-mirror morphologic features. HMC lymphoblast is characterized by an asymmetric foot-like cytoplasmic process that extends from the portion of the cell, thus giving it the light-microscopic appearance responsible for its name. Besides ALL, HMC has been reported in acute myeloblastic leukemia (AML), blastic crisis of chronic myelogenous leukemia, non-Hodgkin's lymphoma, and infectious mononucleosis. HMC has been reported to be prevalent in ALL.L1 and L2 as compared with L3.

UI MeSH Term Description Entries
D008297 Male Males
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D001752 Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%. Blast Phase,Blast Crises,Blast Phases,Crises, Blast,Crisis, Blast,Phase, Blast,Phases, Blast
D001854 Bone Marrow Cells Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells. Bone Marrow Cell,Cell, Bone Marrow,Cells, Bone Marrow,Marrow Cell, Bone,Marrow Cells, Bone
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D014750 Vincristine An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.) Leurocristine,Citomid,Farmistin,Oncovin,Oncovine,Onkocristin,Vincasar,Vincasar PFS,Vincristin Bristol,Vincristin medac,Vincristine Sulfate,Vincrisul,Vintec,cellcristin,PFS, Vincasar,Sulfate, Vincristine

Related Publications

K Uemura, and H Otani, and K Sakamoto, and Y Sakanishi, and T Ota, and T Kobayashi, and N Ariyoshi, and A Shirahata
August 1981, American journal of clinical pathology,
K Uemura, and H Otani, and K Sakamoto, and Y Sakanishi, and T Ota, and T Kobayashi, and N Ariyoshi, and A Shirahata
March 1980, Archives of pathology & laboratory medicine,
K Uemura, and H Otani, and K Sakamoto, and Y Sakanishi, and T Ota, and T Kobayashi, and N Ariyoshi, and A Shirahata
December 1988, Indian pediatrics,
K Uemura, and H Otani, and K Sakamoto, and Y Sakanishi, and T Ota, and T Kobayashi, and N Ariyoshi, and A Shirahata
October 1986, Blut,
K Uemura, and H Otani, and K Sakamoto, and Y Sakanishi, and T Ota, and T Kobayashi, and N Ariyoshi, and A Shirahata
November 1983, Blut,
K Uemura, and H Otani, and K Sakamoto, and Y Sakanishi, and T Ota, and T Kobayashi, and N Ariyoshi, and A Shirahata
March 1984, American journal of clinical pathology,
K Uemura, and H Otani, and K Sakamoto, and Y Sakanishi, and T Ota, and T Kobayashi, and N Ariyoshi, and A Shirahata
February 1981, Thymus,
K Uemura, and H Otani, and K Sakamoto, and Y Sakanishi, and T Ota, and T Kobayashi, and N Ariyoshi, and A Shirahata
April 2020, Journal of pediatric hematology/oncology,
K Uemura, and H Otani, and K Sakamoto, and Y Sakanishi, and T Ota, and T Kobayashi, and N Ariyoshi, and A Shirahata
October 1979, American journal of clinical pathology,
K Uemura, and H Otani, and K Sakamoto, and Y Sakanishi, and T Ota, and T Kobayashi, and N Ariyoshi, and A Shirahata
June 1982, Archives of pathology & laboratory medicine,
Copied contents to your clipboard!